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stand the advice patterns and reasoning behind its decision. Methods: Research 
was conducted using the SMC Advice Directory, of which section contains all SMC 
advice made. The advice published between January 1st 2012 and April 7th 2015 was 
examined. Variables collected include drug name, manufacturer, BNF category, sub-
category, status of orphan drug or/and end of life, submission type, resulting status 
and rationale behind the decision. Data were extracted and collated into one excel 
sheet for the further analysis. Results: During the time period examined, 120 sub-
missions have been made to the SMC. Among these 120 submissions, 46 submissions 
have been accepted for use within NHS Scotland for the indication requested, while 
43 have been accepted for restricted use and 31 have been not recommended. The 
following are the three types of drugs that have been most frequently submitted to 
the SMC for its review: cytotoxic drugs (20 submissions), those used in diabetes (12) 
and those affecting the immune response (10). ConClusions: There have been some 
interesting features of the SMC advice. Nevertheless, due to the small number of the 
advice published during the time period analysed, it is difficult to reach any statisti-
cally valid conclusion regarding its decision-making patterns.
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objeCtives: Pharmaceutical industry continues to grow and drug prices are a bur-
den for countries.Reference price system is assumed that such a practice concern-
ing medicines will lead to a decrease in medicine expenditures as medicine prices 
decrease.The purpose of this analysis is to determine the distribution of the discount 
of original medicines in ATC groups from the reimbursement agency perspective in 
Turkey. Methods: “Detailed Price List” data published on the website of the Ministry 
of Health and “Annex 4-A Funded Medicines List” data published by Social Security 
Institution(SSI) were used.The lists were merged using the Excel software and generic 
medicine including genericized original medicines with different pricing and pay-
ment conditions compared to original medicines with no generics and other specific 
medicines such as blood products,etc. and specific conditions such as medicines with 
no reimbursement were excluded.The analysis was made with a total of 568 original 
medicines with no generic.Ex-factory prices were used in the analysis. Results: The 
original drug distribution examination according to ATC1 groups showed that groups B 
and L had the highest number of original medicines with no generic with 16.55%.The 
price distribution examination according to ATC1 groups showed that the most expen-
sive original medicines with no generic were in group L with 27.31%.The examination 
of SSI discount rates according to ATC1 groups showed that original medicines in group 
S had the highest average discount rate with 46.1%.The ATC1 group with the sec-
ond highest average discount rate,41%,was not specified and identified to be original 
medicines in group M. ConClusions: In ATC1 group the original drugs distribution 
is mostly contains group B and L.The highest-priced original drugs are in ATC1 is in L 
group that is also expected in terms of the properties of L group.The highest discount 
rates are in group S however,the lowest price of original drugs are also in S group.
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objeCtives: Recently, the need for health services has increased gradually and the 
limitations in sources allocated for this area have been recognized. Moving from 
this fact, it has gained a supreme importance to determine what health programs 
or technologies will be given priority. According to Danzon (2001), arrangements 
towards controlling the expenses through price and profit controls, reimbursement 
methods and incentives have recently gained wide currency Methods: This pre-
sent study examines; along with the current situation in Turkey, pharmaceutical 
pricing methods, reimbursement methods and basic health indicators, within the 
scope of changing pharmaceutical policies, in Turkey, obtained results and effects 
of those results so far. Results: Upon the research conducted, it was founded that 
the pharmaceutical policies in Turkey has been effected medicines prices dramati-
cally last few years. Pricing and Reimbursement regulation changed several times 
and but public health expenditure hasn’t decreased. Access to healthcare was main 
factor of health expenditures. Rational drug use was another issue which is main 
aim to Turkish Authorities ConClusions: Although it is natural for Turkey to put 
restrictions on drugs budget to ensure sustainable drug financing, in order to main-
tain the existence of pharmaceutical industry and protect the patients’ access to 
medicines; it would be more favorable in the development of the industry that the 
expectations of the stakeholders in the industry are taken into account in the policy 
making process. This would also help the already supported R&D activities to be 
sustainable as well. The positive and negative aspects of Turkey’s offering the least 
expensive medicine should be examined. Whether being the country to supply the 
least expensive medicine is the correct objective or not in the international arena 
should seriously be discussed. It is recommended that how this situation affects 
Turkey’s image in the outer world should be scrutinized.
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objeCtives: The objective of the study was to determine what is necessary for the 
benefit/risk assessment and estimating the added value (HTAs evaluations) based 
on the experience of previously included innovative products in the Bulgarian posi-
tive list from 2013 till July 2015. Methods: Analysis based on publicly available 
according to their statutes for those vaccinations not defined as mandatory. Vaccines 
are generally to be prescribed by a physician and pharmacies have the obligation to 
provide permanent supply of specific vaccines. The vaccination is conducted by physi-
cians and public health offices. The MoH defines, if the costs of specific vaccinations 
have to be beard by the SHIs other can be provided at no cost by the public health 
offices. The general pricing regulations for pharmaceuticals are applicable as well for 
vaccines however exemptions e.g. of surcharges etc. exist for those defined as manda-
tory vaccinations. Additionally tenders are regular instruments for vaccination buying 
processes. Key differences to the AMNOG are varying stakeholders at different levels 
and responsibilities of those. Pricing might be more flexible with vaccinations even 
though that tenders might apply. ConClusions: The systematic analysis revealed a 
clear market access road map, stakeholder compass and important strategic implica-
tions for the processes along with key differences to the AMNOG.
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objeCtives: The study aimed to determine the differences between countries 
pharmaceutical prices for on-patent medicines using an EKS method Methods: 
The indices were developed using the Fisher Elteto, Koves, Szulc (EKS) method. EKS 
is widely used by the Organisation for Economic Co-operation and Development 
(OECD) but has not yet been applied to pharmaceutical prices. IMS MIDAS data 
was used to estimate prices and sales volumes. In order to construct the indices, 
the products needed to be defined as like. The definition of like in this study was 
based on molecules which are deemed to deliver equivalent health outcomes. The 
price indices were developed for countries with the highest uptake of on patent 
medicines. The analysis compares prices across 9 countries over the period from 
2010 to 2011 and included 27 molecules which were sold in each country for the 
period. Results: US prices were the highest at the end of the period, 1.57; followed 
by France 1.21; Austria 1.11; Australia 1.10; Sweden 1.04; Finland 1.01; The UK 0.94; 
Japan 0.89 and Germany 0.69. Only two countries recorded reasonable increases in 
prices over the period, the USA (4.5% per quarter) and Finland (1.5% per quarter). 
When the simple average of the molecule prices in the countries was compared 
against the EKS method some countries appear to have much higher pricies. In 
particular, Japanese simple average prices are higher with the country being ranked 
4th highest and only 8th on the EKS. Similarly Germany is ranked 6th on the simple 
average and 9th on the EKS. This suggests heavy a substitution effect in these coun-
tries whereby usage shifts to comparatively cheaper molecules. ConClusions: 
This is part of a very large exercise comparing international pharmaceutical prices. 
It also employs a more robust method than previous studies. The analysis shows 
US and French prices to be the highest for on-patent medicines.
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objeCtives: To identify key success factors, barriers, and associated risks with intro-
ducing tiered pricing, defined as non-uniform pricing across customer segments 
in a country within the selected markets to increase patient access. Methods: 
Review of publicly available information including health authority, WHO websites, 
along with peer reviewed journals and other scholarly publications. Primary input 
from fifteen (15) current payers and industry professionals (3 in each country) for 
validation and gap mitigation. Results: Argentina and Mexico have distinct pub-
lic and private-sector based markets with different price expectations. Columbia 
has a single payer, Entidades Promotoras de Salud (EPS), and citizens with private 
insurance are still required to use EPS. The Indonesian healthcare market is highly 
segmented and approximately half of the Indonesian population does not have 
health insurance. Price negotiations are performed at the provider level in both the 
private and public sectors. In Thailand the private health insurance market is small 
and used as supplementary insurance, and the public market is separated into three 
segments (universal “30-Baht” coverage, Social Security Scheme, and Civil Service 
Medical Benefits Scheme). The Civil Service Medical Benefits Scheme (CSMBS) is the 
highest purchaser of high priced oncologics followed by the Social Security Scheme 
(SSS) with the universal “30-Baht” coverage only covering older lower priced/generic 
oncology products. ConClusions: Within the selected markets, Argentina and 
Mexico are the two markets where tiered pricing is straight forward with the private 
and public markets managed independently of each other. The potential for tiered 
pricing in Thailand exists between the CSMBS and the SSS, but less likely to occur 
in the Universal system (30-Baht) or private markets. With Columbia being a single 
payer healthcare system, tiered pricing is non-existent. With provider level price 
negotiations in Indonesia, informal tiered pricing can be in place based on supply 
and demand forces that would influence volumes purchased.
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objeCtives: Given the limited resources and increasing healthcare expenditure, 
a number of countries have established their own health-technology-assessment 
(HTA) bodies. These HTA bodies carry out their own assessments of medicines to 
accept for use the newly licensed medicines that represent good value for money. 
In Scotland, the Scottish Medicines Consortium (SMC) is responsible for such role 
as it reviews information supplied by the manufacturers and provides advice to the 
National Health Service (NHS) in Scotland. The purpose of this research is to examine 
the SMC formal advice following its assessment of products in order to better under-
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would seem most relevant to different stakeholders. Methods: A landscape review 
was performed in Medline and EMBASE. Initial search retrieved over 2000 articles. 
After a selection based on reference to healthcare, policy issues, or social justice, 
64 papers were included. Data were extracted and a full table was made, including 
all arguments found; next, identical or largely overlapping criteria were excluded 
and a reduced set was compiled. Results: The final set included 26 arguments, 
categorized by type (clinical, social justice, ethical, and policy). Examples of argu-
ments included in the final set are: Longevity, need, dignity and public health value. 
For each argument, relevance to stakeholders was scored on three levels (not, partly, 
and completely relevant). ConClusions: Many arguments play a role in making 
decisions about patient treatments, but not all are relevant to all interventions. 
Moreover, they may interact with each other. Therefore, systematic and analytical 
approaches such as multi-criteria decision analysis may be not suitable. As such, a 
viable way to deal with interacting and possibly conflicting arguments might be to 
arrange public discussions that would evoke different stakeholders’ perspectives.
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objeCtives: FDA breakthrough therapy designation was created in 2012 to expedite 
the registration of new health care technologies for use by patients with serious or 
life-threatening diseases/conditions. Breakthrough therapies are eligible for other 
FDA regulatory programs such as fast track designation, accelerated approval and 
priority review. We sought to determine whether other regulators and HTA agen-
cies/payers also sought to expedite access to these therapies. Methods: The FDA 
website was examined to identify breakthrough therapy medicines that had been 
approved up to 31 December 2014. The websites of the EMA (EU), Health Canada and 
TGA (Australia) were examined to determine their corresponding registration status. 
The NICE (England), IQWiG (Germany), TC (France), CADTH/pCODR (Canada) and 
PBAC (Australia) websites were examined to determine if and when the medicines 
had been considered for reimbursement/coverage. Results: The FDA approved 
14 breakthrough medicines as at 31 December 2014 for use in 16 unique patient 
populations (i.e. pairings). The mean time from submission to approval was 164 
days. Twelve pairings are orphan drugs and 9 are for patients with cancer. As of 
20 June 2015, 13 had been registered in the EU (mean time 326 days), 8 in Canada 
(275 days) and 9 in Australia (N/A). Four of the 15 pairings had been assessed by 
NICE (all recommended), 5 by IQWiG (4 additional benefit not quantifiable, 1 minor 
additional benefit), 6 by the TC (ASMR rating = II (2), III (1), IV (1), V (2)), 8 by CADTH/
pCODR (6 recommended, 2 not recommended) and 7 by the PBAC (all recom-
mended). ConClusions: Most of the 16 pairings were registered first in the US. 
The FDA evaluation period was shorter compared to other regulatory agencies. Some 
HTA agencies are yet to consider many pairings whilst others have dissimilar views 
on their additional clinical benefit.
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objeCtives: This research aims to characterize the extent to which health tech-
nology assessment (HTA) is currently being used to determine pharmaceutical 
coverage in the Middle East and North Africa (MENA) region. The objectives are 
to understand which decision-makers are currently undertaking this activity, the 
extent of its formalization, and in which parts of the healthcare system in each 
country there is greatest appetite for its implementation. Methods: In-depth, 
qualitative interviews were conducted with a total of 11 payer decision-makers 
and 20 industry stakeholders in Egypt, Saudi Arabia, Turkey and the United Arab 
Emirates (UAE). Published literature and government websites were also reviewed. 
Primary and secondary research focused on current and evolving reimbursement 
decision-making procedures in these countries in addition to potential policy 
reforms. Results: Of the countries considered, HTA focused on evaluation of 
specific pharmaceuticals appears to have gained the most traction in Saudi Arabia, 
where one of the public-sector payers has begun undertaking in-depth pharma-
coeconomic (PE) analysis. In Egypt, while a PE unit has been established, its pre-
sent role is to support the country’s Drug Pricing Committee on a case-by-case 
basis. In Turkey, while PE data is required for reimbursement submission, budget 
impact is reported to remain the primary driver of national-level decision-mak-
ing. Meanwhile, in the UAE, there is little evidence that the insurers increasingly 
responsible for coverage under the country’s healthcare reforms are using formal 
HTA. ConClusions: The extent of HTA formalization and the specific areas of 
the healthcare system in which HTA operates vary across the MENA region, in 
line with the broader policy framework. Champions of further HTA development 
come from diverse stakeholder groups in each country. With time, it is expected 
that HTA will gain increasing traction across MENA, alongside arrangements 
such as risk-sharing schemes, with significant consequences for pharmaceutical 
access.
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objeCtives: Examine orphan drugs assessed by the German Federal Joint 
Committee (G-BA) between January 2011 and May 2015 and compare their 
assessments with those of other international HTA agencies. Methods: GBA 
guidlines and pricing and reimbursement legislation. Results: The survey analyses 
pharmacoeconomic guideline of the National Council on prices and reimburse-
ment for inclusion of new INN in the positive drug list in Bulgaria. Requirements 
for efficacy, safety, benefits, adverse events, comparator, standard treatment, drug 
utilization, budget impact, patient population during the premarketing and post-
marketing period are change in order to provide data with higher quality for the 
decision making process . From April 2013 to July 2015. Over that period more than 
36 new INNs were accepted for reimbursement in Bulgaria. A guideline with an HTA 
approach for assessment of submitted dossiers was introduced in April 2015 The 
experience in that field of other MSs is summarized and compared. ConClusions: 
The study evaluates how NCPR develops recommendations and reimbursement 
decisions on the basis of one step procedure which shortens the pricing and reim-
bursement process in comparison with other EU MSs. No published criteria how to 
evaluate the submitted pharmacoeconomic information by the expert of the NCPR 
are publicly available and HTA appraisal may be subjectively biased.
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objeCtives: For orphan drugs an additional benefit is granted by market authori-
zation of the EMA. In case orphan drugs exceed an annually turnover of 1m Euro 
(based on ex. pharmacy prices) in the outpatient sector recently authorized orphan 
drugs have to undergo an assessment of the additional benefit extent by the Federal 
Joint Committee. Based on the results pharmaceutical manufacturer and the head 
association of the statutory health insurance negotiate rebates. The objective of this 
analysis is to assess whether the additional benefit extent of orphan drugs does 
impact the rebate size of the price negotiations. Methods: In a first step orphan 
drugs affected by an assessment of additional benefit extent were analyzed within 
the German market. The dependency between additional benefit extent and rebate 
size of negotiations is assessed by correlation analysis. This analysis is based on 
relevant public available data of the Federal Joint Committee as well as price related 
rebate information related to the AMNOG process for orphan drugs. Results: By 
May 2015, 10 of currently 77 in Germany registered orphan drugs passed the AMNOG 
legislation comprising the assessment of additional benefit extent as well as associ-
ated price negotiations. Thereby rebates sizes ranging from 9% up to almost 44%. 
The analysis of the additional benefit extent and the rebate size showed no correla-
tion between the two parameters. ConClusions: The hypothesis of an inversely 
proportional dependence between additional benefit extent and rebate size was 
refuted by this analysis. Following this a larger benefit extent tends not to impact 
price negotiations in terms of a rebate reduction. However, the small sample size 
tends to limit power of the analysis.
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objeCtives: Canadian provinces are encouraged to follow HTA recommendations 
conducted under pCODR for cancer drugs, but have ultimate authority over the 
final reimbursement decision on public drug plans. In order to understand the 
impact of HTA assessments on market access of oncology drugs and highlight vari-
ations across the individual jurisdictions we conducted a quantitative analysis of 
all pCODR’s oncology assessments completed in 2013-14 and consequent fund-
ing decisions implemented by the provinces. Methods: Data, obtained from the 
pCODR database for all 27 assessments completed in 2013 and 2014, were used to 
estimate median time to pCODR final decision and the time to first funding approval 
in one of the nine provinces excluding Quebec. We also examined the probability 
of obtaining public drug plan approval in Canada based on the pCODR recommen-
dation. Results: On average, 74% of the assessments resulted in a favourable 
decision by the provinces, compared to 88% with a favourable pCODR recommen-
dation. However, positive provincial funding decisions varied considerably (88% in 
Ontario, Manitoba, and Saskatchewan, to 32% in Prince Edward Island). At the time 
of analysis 16% of drugs were still awaiting provincial funding assessment, while 
10% received no funding primarily after a “no funding” pCODR recommendation. 
The median time between marketing approval and a final pCODR decision was 200 
days; the median time between that final decision and receiving the first fund-
ing approval was 115 days. Provincial funding decisions under pCPA joint negotia-
tions took longer (median of 118 days) compared to those negotiated separately (80 
days). ConClusions: It takes nearly four months for provinces to begin funding 
new drugs after a final HTA decision is issued, with funding decisions in other 
jurisdictions lagging further behind. Multiple levels of pricing and reimbursement 
regulations and a highly fragmented pharmaceutical market are likely impacting 
market access for new drugs in Canada.
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objeCtives: The healthcare sector is evolving while life expectancy is increasing. 
These trends put greater pressure on resources, prompt reforms, and demand trans-
parent arguments and criteria to assess the overall value of health interventions. 
Besides (cost) effectiveness, many criteria play a role when determining the value 
of interventions. There is no consensus on the core arguments. This study aimed at 
retrieving the most widely recognized arguments used in making decisions about 
patient treatments and prioritizing interventions, and to compile a smaller set that 
